0000882104-12-000011.txt : 20120606
0000882104-12-000011.hdr.sgml : 20120606
20120606182400
ACCESSION NUMBER: 0000882104-12-000011
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20120605
FILED AS OF DATE: 20120606
DATE AS OF CHANGE: 20120606
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FRANK FRED
CENTRAL INDEX KEY: 0001181155
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19756
FILM NUMBER: 12892957
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PDL BIOPHARMA, INC.
CENTRAL INDEX KEY: 0000882104
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943023969
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 932 SOUTHWOOD BLVD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
BUSINESS PHONE: 775-832-8500
MAIL ADDRESS:
STREET 1: 932 SOUTHWOOD BLVD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE
DATE OF NAME CHANGE: 19930328
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0305
4
2012-06-05
0
0000882104
PDL BIOPHARMA, INC.
PDLI
0001181155
FRANK FRED
C/O PDL BIOPHARMA, INC.
932 SOUTHWOOD BOULEVARD
INCLINE VILLAGE
NV
89451
1
0
0
0
Common Stock
2012-06-05
4
A
0
7924
6.31
A
33296
D
1. The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL Biopharma, Inc. During the one-year vesting period, the grant recipient will have the right to vote the shares and receive any dividends and other distributions paid, except that dividends and other distribuitons will be accumulated and will vest and be paid, with interest, on the earlier of the same vesting conditions as the original award or March 15th of the year following the payment of such dividend or distribuiton to all stockholders.
/s/Danny J. Hart, Jr., Attorney-in-Fact, for Frederick Frank
2012-06-06
EX-24
2
frank.txt
POWER OF ATTORNEY
POWER OF ATTORNEY
The undersigned hereby constitutes and appoints Danny J Hart, Jr. and
Christopher Stone, and each of them, his or her, true and lawful
attorney-in-fact to:(1) prepare, execute in the undersigned's name
and on the undersigned's behalf, and submit to the U.S. Securities
and Exchange Commission (the "SEC") a Form ID, including amendments
thereto, and any other documents necessary or appropriate to obtain
codes and passwords enabling the undersigned to make electronic
filings with the SEC of reports required by Section 16(a) of the
Securities Exchange Act of 1934 or any rule or regulation of the SEC;
(2) execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director, and/or person who holds more
than 10% of the stock of PDL BioPharma, Inc. (the "Company"), Forms
3, 4 and 5 in accordance with Section 16(a) of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and the rules
thereunder;(3) do and perform any and all acts for and on behalf of
the undersigned which may be necessary or desirable to complete and
execute any such Form 3, 4 or 5, complete and execute any amendment(s)
thereto, and timely file any such form with the United States
Securities and Exchange Commission and any stock exchange or similar
authority; and (4) take any other action of any type whatsoever in
connection with the foregoing which, in the opinion of such
attorney-in-fact, may be of benefit to, in the best interest of, or
legally required by, the undersigned, it being understood that the
documents executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power of Attorney shall be in such form and shall contain
such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.The undersigned hereby grants to each such
attorney-in-fact full power and authority to do and perform any and every
act and thing whatsoever requisite, necessary or proper to be done in the
exercise of any of the rights and powers herein granted, as fully to all
intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying
and confirming all that such attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall lawfully do or cause to be done pursuant
to this power of attorney. The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked or modified by the undersigned in a signed
writing, but shall terminate automatically as to each individual
attorney-in-fact when such person is no longer an employee of the Company.
This Power of Attorney may be filed with the SEC as a confirming statement
of the authority granted herein. The undersigned has caused this Power of
Attorney to be executed as of this day of April, 2012. By.t).).Printed
name:Frederick Frank